In a randomized trial of participants with treatment-resistant depression, the TNFα inhibitor infliximab reduces depression scores, but only in the subpopulation of patients displaying elevation of the inflammatory marker C-reactive protein (25). The gene discussed is TNF; the disease is depressive symptom measurement.